Thursday, November 17, 2011
Curis Inc., of Lexington, Mass., reported preclinical data showing that CUDC-907, a small-molecule inhibitor designed to target both PI3K and HDAC, had broad activity in hematologic cancer models. The company said it anticipates filing an investigational new drug application during the first half of 2012.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.